Cargando…
P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
Autores principales: | Bobin, A., Manier, S., De Keizer, J., Karlin, L., Perrot, A., Hulin, C., Caillot, D., Mariette, C., Lenain, P., Richez, V., Tiab, M., Touzeau, C., Jaccard, A., Decaux, O., Araujo, C., Belhadj, K., Benboubker, L., Déal, C., Macro, M., Vincent, L., Arnulf, B., Bareau, B., Braun, T., Calmettes, C., mamoun, D., Zerazhi, H., Demarquette, H., Feugier, P., Fohrer-sonntag, C., Godet, S., Petillon, M.-O., Avet-Loiseau, H., Leleu, X. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430559/ http://dx.doi.org/10.1097/01.HS9.0000846440.48761.8d |
Ejemplares similares
-
P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).
por: Macro, Margaret, et al.
Publicado: (2023) -
P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
por: Macro, M., et al.
Publicado: (2022) -
P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
por: Hulin, C., et al.
Publicado: (2022) -
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022) -
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
por: Macro, M., et al.
Publicado: (2023)